Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.
相关临床试验
5
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2017
已完成
2
40.0%
尚未招募
1
20.0%
招募中
2
40.0%
暂无批准数据
- Design Therapeutics has appointed industry veteran Justin Gover to its Board of Directors, bringing over 25 years of biotechnology leadership experience to the clinical-stage genetic disease company. - Gover previously served as founding CEO of GW Pharmaceuticals for over two decades, leading the company through its $7 billion acquisition by Jazz Pharmaceuticals in 2021 and the successful commercialization of Epidiolex for childhood epilepsies. - The appointment comes as Dr. Arsani William stepped down from the board, having provided strategic guidance since 2021 including through the company's IPO and clinical pipeline advancement. - Design Therapeutics is developing GeneTAC gene targeted chimera small molecules to modulate disease-causing gene expression, with clinical programs targeting Friedreich ataxia and Fuchs endothelial corneal dystrophy.
- Design Therapeutics will present safety findings from its Phase 1 trial of DT-168, a potential first disease-modifying eye drop treatment for Fuchs endothelial corneal dystrophy, at Eyecelerator @ Park City 2025 on May 2. - DT-168 is a GeneTAC® small molecule designed to target the genetic cause of FECD by reducing expression of mutant TCF4 gene products that lead to corneal endothelial cell dysfunction. - The company aims to advance DT-168 to Phase 2 clinical trials in FECD patients, potentially offering an alternative to corneal transplant surgery for a disease that currently has no disease-modifying treatments.
- Design Therapeutics has appointed Chris Storgard, M.D., as Chief Medical Officer, bringing over two decades of leadership in drug development with experience advancing multiple assets through global regulatory approvals. - Dr. Storgard previously served as CMO at ADARx Pharmaceuticals and Heron Therapeutics, where he secured U.S. and European approvals for several products in oncology and acute care. - The appointment comes at a strategic time as Design Therapeutics advances its portfolio of GeneTAC® small molecules targeting serious degenerative genetic diseases, including its lead program for Friedreich ataxia.
